Sugi Predict

Sugi Predict / Compounds / SCHEMBL29538

SCHEMBL29538

SCHEMBL29538

NC(=O)c1cc2ccccc2nc1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 1/20 0.69
▸ ALDH1A1 P00352 5/20 0.45
▸ MAPT P10636 4/20 0.45
▸ HPGD P15428 3/20 0.45
▸ GLA P06280 1/20 0.45
▸ ACHE P22303 1/20 0.45
▸ KDM4E B2RXH2 6/20 0.44
▸ GAA P10253 3/20 0.44
▸ TSHR P16473 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ NCOA1 Q15788 2/20 0.43
▸ NCOA3 Q9Y6Q9 2/20 0.43
▸ STAT3 P40763 1/20 0.43
▸ IRAK4 Q9NWZ3 1/20 0.42
▸ HTT P42858 2/20 0.41
▸ LCK P06239 1/20 0.41
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ GALR3 O60755 1/20 0.40
▸ NR2F2 P24468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL352221 0.83 IKBKB (0.51) IKBKBALDH1A1MAPTHPGDGLA
SCHEMBL31133499 0.83 IKBKB (0.51) IKBKBALDH1A1MAPTHPGDGLA
SCHEMBL9665736 0.83 IKBKB (0.53) IKBKBALDH1A1MAPTHPGDGLA
SCHEMBL30837 0.81 IKBKB (1.00) IKBKBALDH1A1MAPTHPGDGLA
SCHEMBL2099350 0.81 IKBKB (0.69) IKBKBALDH1A1MAPTHPGDGLA
SCHEMBL31060123 0.81 IKBKB (1.00) IKBKBALDH1A1MAPTHPGDGLA
SCHEMBL31301 0.80 IKBKB (0.67) IKBKBALDH1A1MAPTHPGDGLA
SCHEMBL22388 0.80 IKBKB (0.67) IKBKBALDH1A1MAPTHPGDKDM4E
SCHEMBL7673682 0.80 IKBKB (0.67) IKBKBALDH1A1MAPTHPGDGLA
SCHEMBL1723156 0.80 IKBKB (0.67) IKBKBALDH1A1MAPTHPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014086453-A1 AZAHETEROBICYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2014-06-12 — — WO claimed
US-8513421-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-08-20 — — US claimed
EP-1042295-A1 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2000-10-11 — — EP claimed
WO-1999032450-A1 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 1999-07-01 — — WO claimed
WO-2025085233-A1 NOVEL DERIVATIVES OF QUINOLINONES, AND COMPOSITIONS AND METHODS THEREOF ENSEM THERAPEUTICS, INC. (US) 2025-04-24 — — WO disclosed
US-20230101819-A1 SMYD Inhibitors EPIZYME INC (US) 2023-03-30 — — US disclosed
US-20210198252-A1 SMYD INHIBITORS EPIZYME INC (US) 2021-07-01 — — US disclosed
US-20190322660-A1 SMYD INHIBITORS Epizyme, Inc. 2019-10-24 — — US disclosed
US-10266526-B2 Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer Epizyme, Inc. (US) 2019-04-23 — — US disclosed
US-20170355695-A1 SMYD Inhibitors Epizyme, Inc. (US) 2017-12-14 — — US disclosed
CN-103068804-B Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators GRUNENTHAL GMBH (DE) 2015-08-19 — — CN disclosed
CN-103068804-B Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators GRUNENTHAL GMBH (DE) 2015-08-19 — — CN disclosed
US-20120053205-A1 Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators Grünenthal GmbH (DE) 2012-03-01 — — US disclosed
US-20120053205-A1 Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators Grünenthal GmbH (DE) 2012-03-01 — — US disclosed
WO-2012025236-A1 SUBSTITUTED 2-OXY-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2012-03-01 — — WO disclosed
WO-2011146591-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-11-24 — — WO disclosed
US-20110288117-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-11-24 — — US disclosed
EP-1042295-A1 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2000-10-11 — — EP disclosed
US-6093732-A PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION PHARMACIA & UPJOHN COMPANY (US) 2000-07-25 — — US disclosed
WO-1999032450-A1 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 1999-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053205-A1 Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators KCNQ1, KCNQ2, KCNQ3 IKBKB 667/4885ALDH1A1 3218/4885MAPT 3171/4885
US-10266526-B2 Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer SMYD3, SMYD2, SNRPD3 IKBKB 1057/4885ALDH1A1 1204/4885MAPT 3644/4885
US-20170355695-A1 SMYD Inhibitors SMYD3, SMYD2, SMURF2 IKBKB 1057/4885ALDH1A1 1533/4885MAPT 3529/4885
US-20210198252-A1 SMYD INHIBITORS SMYD3, SMYD2, SMURF2 IKBKB 1027/4885ALDH1A1 1575/4885MAPT 3568/4885
US-20110288117-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 IKBKB 315/4885ALDH1A1 487/4885MAPT 2029/4885
US-20190322660-A1 SMYD INHIBITORS SMYD2, SMYD3, SMURF2 IKBKB 986/4885ALDH1A1 1125/4885MAPT 4031/4885
US-20230101819-A1 SMYD Inhibitors SMYD3, SMYD2, SMURF2 IKBKB 1061/4885ALDH1A1 1611/4885MAPT 3554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.